Press releases
- Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
- Legend Biotech to Participate in the Jefferies Global Healthcare Conference
- Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
- Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
- NantHealth Welcomes Marc Harrison as Chief Legal Officer to Executive Team
- CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
- Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
- Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
More ▼
Key statistics
As of last trade Legend Biotech Corp (9LB:BER) traded at 38.60, 6.63% above its 52-week low of 36.20, set on Jun 03, 2024.
52-week range
Open | 38.60 |
---|---|
High | 38.80 |
Low | 38.60 |
Bid | 37.20 |
Offer | 40.00 |
Previous close | 39.20 |
Average volume | 17.40 |
---|---|
Shares outstanding | 182.28m |
Free float | 180.09m |
P/E (TTM) | -- |
Market cap | 7.56bn USD |
EPS (TTM) | -2.60 USD |
Data delayed at least 15 minutes, as of Jun 18 2024 13:45 BST.
More ▼